CD274 and neoplasm: At present, tissue-based biomarkers including PD-L1 expression level, tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repair (MMR) gene defect and TIL have been proved to be reliable in predicting the effectiveness of immunotherapy for NSCLC (66, 67).